Smith Darren Charlton 4

What Happened

• Darren Charlton Smith, Chief Financial Officer of Telix Pharmaceuticals Ltd (TLX), exercised 1,111 share rights (SRs) on March 29, 2026 and acquired 1,111 common shares at an exercise price of $0. The Form 4 also shows a simultaneous "Disposition (Derivative)" for 1,111 SRs at $0, which reflects the conversion/exercise of the derivative instrument rather than a market sale.

Key Details

• Transaction date: 2026-03-29; Form 4 filed: 2026-04-01.
• Reported price: $0.00 per share (exercise price); total cash paid: $0.
• Shares acquired: 1,111; same number shown as disposed of as a derivative instrument (conversion).
• Footnote: The share rights were granted on Jan 1, 2025 and became vested and exercisable on Mar 5, 2026.
• Shares owned after the transaction: not specified in the provided filing excerpt.
• Timeliness: Filed Apr 1 for a Mar 29 transaction — this appears to be one business day later than the typical two-business-day Form 4 deadline.

Context

• This was an exercise of share rights (derivative conversion), not an open-market purchase or sale. Because the exercise price was $0 and no sale of the resulting shares was reported, this increases the insider’s reported shareholdings (unless other undisclosed transactions occurred).
• Such exercises are often routine following vesting and do not by themselves indicate a bullish or bearish signal; they simply convert granted rights into ordinary shares.